

NeuroMetrix Announces Issuance of New U.S. Patent for Automated Control of Quell Therapy During Sleep

WALTHAM, Mass.--(BUSINESS WIRE)-- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that the U.S. Patent and Trademark Office has issued U.S. Patent No. 9,731,126. The patent covers novel technology whereby the Quell® device automatically modulates therapeutic neurostimulation based on the user's sleep characteristics. In addition, the patent includes claims related to providing device users with feedback about their sleep.

Most people with chronic pain experience sleep disorders, most often insomnia. Inadequate sleep worsens pain symptoms, which can precipitate a vicious cycle of decreased activity during the day and even less sleep at night. Quell is uniquely positioned to address the impact of chronic pain on sleep. It is the only transcutaneous electrical nerve stimulator cleared by the FDA for use during sleep that is available over the counter. Quell also measures and tracks sleep data to help users understand the amount and quality of their sleep. These measurements are available via the Quell smartphone app and Quell Health Cloud.

"Chronic pain can be extremely disruptive to one's quality of life. Many people find that their pain tends to increase throughout the day and peak at night. Unfortunately, those higher levels of pain can prevent them from getting to sleep and staying asleep," said Shai N. Gozani, M.D., Ph.D. "We are therefore particularly pleased to have received this latest patent for automated regulation of Quell therapy during sleep. This patent further expands our wearable pain relief intellectual property assets and enhances our long-term competitive position."

About Quell

Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.

About NeuroMetrix

NeuroMetrix is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company's lead product is Quell®, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit NeuroMetrix.com.

View source version on [businesswire.com](http://www.businesswire.com): <http://www.businesswire.com/news/home/20170815005337/en/>

NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
Chief Financial Officer
neurometrix.ir@neurometrix.com

Source: NeuroMetrix, Inc.

News Provided by Acquire Media